16 research outputs found
Factors influencing eating behavior of Benghazi University students
Background: University students are more exposed to new individual and environmental influences. This transition period is considered as a risky life phase because it’s characterized by changing in physical and social status as well as changing in the lifestyle that will affect the eating behavior of students. Aims and Objectives: The current study aimed to determine the factors influencing the eating behaviors of Benghazi University students. Materials and Methods: A cross sectional study was undertaken for a period from January to May 2019 in Benghazi University. Samples of 300 students were requested to fill out a questionnaire. SPSS was used to analyze the data. Results: After starting university, (64%) of students stated that they had a change in eating behavior and (59%) of participants reported unhealthy eating pattern. About (67%) of students had a sedentary lifestyle with the majority of them were having unhealthy eating patterns (P value = 0.000). According to the BMI the majority of students had normal weight (62.6%). About (80%) of student reported that the lack of time to prepare a healthy meal during study period was effective and More than half of the students reported that inaccessibility of healthy food, student’s positive emotions, poor knowledge of healthy food, and stress associated with exams period were effective. There was a statistical difference between student’s eating patterns and poor knowledge, lack of time, stress, body weight concerns, negative emotions, peer pressure, lack of parental control, mass media and social life (P value < 0.05). Conclusion: This study concluded that the majority of students undergo a negative shift in their eating and lifestyle after starting university, and there is statistical difference between many factors and student’s eating pattern
Association of TPH-1 and TPH-2 gene polymorphisms with suicidal behavior: a systematic review and meta-analysis
Schwannome du penis (A propos d'une observation)
No Abstract. African Journal of Urology Vol. 12(2) 2006: 109-11
Kyste hydatique rétrovésical : aspects diagnostiques et thérapeutiques
Objectif: Déterminer les aspects cliniques, radiologiques, étio-pathogéniques et chirurgicaux des localisations rétrovésicales du kyste hydatique.
Patients et méthodes: De 1988 à 2005, 8 patients présentant un kyste hydatique rétro-vésical (KHRV) ont été hospitalisés et opérés au sein du service d\'urologie de l\'Hôpital Militaire Universitaire Mohammed V, Rabat, Maroc. L\'âge moyen des patients était de 44 ans. Les signes d\'irritation vésicale étaient les motifs les plus fréquents de consultation. Un seul cas d\'hydaturie a été noté.
Résultats: Une kysto-périkystectomie partielle a été réalisée chez tous les patients. Les suites étaient simples. Un seul patient a présenté une fi stule urinaire ayant bien évolué avec tarissement à 3 mois.
Conclusion: La localisation rétro-vésicale du kyste hydatique est rare et le traitement est avant tout chirurgical. African Journal of Urology Vol. 14 (1) 2008: pp. 37-4
Recommended from our members
Abstract 1949: KRAS G12C mutations in Hispanic and non-Hispanic patients with NSCLC: clinicopathologic characteristics and prognosis
Abstract Background: KRAS mutations, which are associated with tobacco use, have been linked to worse survival in patients with non-small cell lung cancer (NSCLC). KRAS G12C is the most frequent actionable mutation detected in NSCLC, with a prevalence of 13%. The incidence of KRAS G12C mutations and potential impact on treatment response for Hispanic patients with lung cancer has not been well characterized. Methods: A total of 110 patients (77 non-Hispanic [NH] and 33 Hispanic) with a diagnosis of NSCLC and next generation sequencing information available treated at the University of Miami from 2013-2021 were included. Incidence of KRAS G12C mutations, clinicopathologic characteristics, treatment response and overall survival were analyzed. Results: The prevalence of the KRAS G12C mutation was 7.6% in the whole cohort. The prevalence of KRAS G12C co-mutations in NH vs Hispanic was 9.3% vs 5.7%. Median age of NH vs Hispanic patients was 69.5 yrs vs 66.4 yrs. (Table 1) In both the NH and Hispanic cohorts, there were more women (56% vs 51.5%), as well as smokers (97% vs 97%). In both cohorts, most patients had non-squamous histology (94%). In the NH cohort, the majority were PDL1 negative (50%). In the Hispanic cohort, there was a more even distribution of PDL1 expression status: negative (30%), low (33%), and high (24%). Median DOR for chemotherapy in NH vs Hispanics was 16 mos vs 14 mos (p=0.77). Median DOR for immunotherapy in NH vs Hispanics was 18 mos vs 12 mos (p=0.30). Median OS in NH vs Hispanics was 36 mos vs 29 mos (p=0.25). Conclusion: There was no statistical difference in prevalence of KRAS G12C mutations between NH and Hispanics. Notably, both cohorts had a significant smoking history. KRAS G12C portends equally poor prognosis and treatment resistance as evidenced by median DOR and OS for both Hispanics and NH patients. However, Hispanic patients demonstrated a trend of decreased OS and DOR to IO compared to NH patients. Clinicopathologic characteristics and prognosis of NH and Hispanic Patients with KRAS G12C mutation `Characteristic Non-Hispanic (n = 77) Hispanic (n =33 ) P Value Total Patients (%) 77 (70%) 33 (30%) Status 37(48%) 14(42%) Alive(%) 40(52%) 19(58%) Deceased(%) Median Age (Years [Range]) 69.5 (47-92) 66.4 (41-84) 0.13 Gender 34(44%) 17(52%) Male(%) 43(56%) 16(48%) Female(%) Race 70(91%) 32(97%) White(%) 4(5%) 1(3%) African American(%) 1(1%) 0(0%) Asian (%) 2(3%) 0(0%) Other(%) Tobacco Use 2(3%) 1(3%) Never(%)1 Pack/Day(%) Histology 73(94%) 31(94%) Non-squamous(%) 2(3%) 0(0%) Squamous(%) 2(3%) 2(6%) Mixed/Other(%) PD-L1 Status 39(50%) 10(30%) Negative(%) 13(17%) 11(33%) Low expression(50%)(%) 12(16%) 4(13%) Unknown(%) Stage 1(1%) 1(3%) IA(%) 5(6%) 2(6%) IB(%) 3(4%) 0(0%) IIA(%) 4(5%) 3(9%) IIB(%) 11(15%) 4(12%) IIIA(%) 4(5%) 0(0%) IIIB(%) 46(60%) 22(67%) IV(%) 3(4%) 1(3%) Unknown(%) Metastases* 487(12%) 265(17%) Any metastasis/multiple sites 2(4%) 0(0%) Lung 5(9%) 3(11%) Liver 13(22%) 7(25%) Adrenal 18(31%) 9(33%) Bone 13(22%) 4(14%) Brain Other Chemotherapy 20(26%) 10(31%) No Chemotherapy(%) 28(36%) 12(36%) Platinum + Pemetrexed(%) 6(8%) 1(3%) Platinum + Taxane(%) 4(5%) 8(24%) Chemotherapy + Immunotherapy(%) 9(12%) 1(3%) Single Agent Chemotherapy(%) 10(13%) 1(3%) Unknown(%) Median duration of response to chemotherapy 14 months 16 months 0.77 Immunotherapy 27(35%) 18(54%) Yes(%) 40(52%) 13(40%) No(%) 10(13%) 2(6%) Unknown(%) Median duration of response to immunotherapy 18 months 12 months 0.30 Median Survival Time 36 months 29 months 0.25 Median Survival Time in Stage IV Patients 29 months 20 months 0.92 *Percentages may not equal 100 Citation Format: Aysswarya Manoharan, Samuel A. Kareff, Leana M. Ramos, Nora A. El-Abbar, Gilberto Lopes, Estelamari Rodriguez. KRAS G12C mutations in Hispanic and non-Hispanic patients with NSCLC: clinicopathologic characteristics and prognosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1949
The Campylobacter jejuni Response Regulator and Cyclic-Di-GMP Binding CbrR Is a Novel Regulator of Flagellar Motility
A leading cause of bacterial gastroenteritis, Campylobacter jejuni is also associated with broad sequelae, including extragastrointestinal conditions such as reactive arthritis and Guillain-Barré Syndrome (GBS). CbrR is a C. jejuni response regulator that is annotated as a diguanylate cyclase (DGC), an enzyme that catalyzes the synthesis of c-di-GMP, a universal bacterial second messenger, from GTP. In C. jejuni DRH212, we constructed an unmarked deletion mutant, cbrR−, and complemented mutant, cbrR+. Motility assays indicated a hyper-motile phenotype associated with cbrR−, whereas motility was deficient in cbrR+. The overexpression of CbrR in cbrR+ was accompanied by a reduction in expression of FlaA, the major flagellin. Biofilm assays and scanning electron microscopy demonstrated similarities between DRH212 and cbrR−; however, cbrR+ was unable to form significant biofilms. Transmission electron microscopy showed similar cell morphology between the three strains; however, cbrR+ cells lacked flagella. Differential radial capillary action of ligand assays (DRaCALA) showed that CbrR binds GTP and c-di-GMP. Liquid chromatography tandem mass spectrometry detected low levels of c-di-GMP in C. jejuni and in E. coli expressing CbrR. CbrR is therefore a negative regulator of FlaA expression and motility, a critical virulence factor in C. jejuni pathogenesis